The back and forth between Republicans and Democrats over the scope of health extenders and offsets to include in Congress’ upcoming continued resolution has resulted in bipartisan agreement on a package that includes long-sought reforms to pharmacy benefit managers’ practices in Medicare, Medicaid and the commercial market, as well as measures to streamline the generic drug approval process and rein in brand drug makers’ use of so-called patent thickets to delays generic and biosimilar competition.